-

Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will participate in a fireside chat at the virtual Goldman Sachs Annual Global Healthcare Conference on Thursday, June 11, 2020 at 10:30 a.m. EDT.

A live webcast of the fireside chat will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 90 days on Karuna’s website following the conference.

About Karuna

Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.

Contacts

Investor Contact:
Alexis Smith
518-338-8990
asmith@karunatx.com

Media Contact:
Jenn Gordon
GlobalHealthPR
202-587-2580
jgordon@globalhealthpr.com

Karuna Therapeutics, Inc.

NASDAQ:KRTX

Release Versions
$Cashtags

Contacts

Investor Contact:
Alexis Smith
518-338-8990
asmith@karunatx.com

Media Contact:
Jenn Gordon
GlobalHealthPR
202-587-2580
jgordon@globalhealthpr.com

More News From Karuna Therapeutics, Inc.

Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP)...

Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced financial results for the first quarter of 2020 and provided a general business update. “We are off to a strong start in 2020 and continue to make significant progress advancing our lead program,...

Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the appointment of Christopher J. Coughlin to its board of directors. Mr. Coughlin will chair Karuna’s audit committee. “We are thrilled to have Chris join our board,” stated Steve Paul, M.D., chief executiv...
Back to Newsroom